Paratek Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch PRTK and buy or sell other stocks, ETFs, and their options commission-free!About PRTK
Paratek Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI), and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
CEOEvan Loh, MD
CEOEvan Loh, MD
Employees—
Employees—
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded1996
Founded1996
Employees—
Employees—
PRTK Key Statistics
Market cap127.83M
Market cap127.83M
Price-Earnings ratio-2.00
Price-Earnings ratio-2.00
Dividend yield—
Dividend yield—
Average volume1.55M
Average volume1.55M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$3.65
52 Week high$3.65
52 Week low$1.29
52 Week low$1.29